Current position in this corpus
Not all organoid workflows in this corpus are developmental hPSC differentiations. A major branch instead expands adult, fetal, or patient-derived tissue into organoid platforms that are closer to donor biology and often more immediately translational.
Strong supporting sources
Working synthesis
- These protocols are strongest when donor context, tumor state, or long-term expandability matter more than recapitulating early embryogenesis.
- They also tend to be the quickest route into perturbation, drug screening, or xenotransplantation once tissue access is solved.
- The main tradeoff is that they often preserve epithelial or disease-specific features better than they capture whole-organ developmental context.
Main tension
- developmental fidelity versus donor or disease specificity
- expandable epithelial platforms versus multicompartment organ complexity
Open questions
- When should a project start from patient-derived tissue rather than from pluripotent differentiation?
- Which missing stromal, immune, or vascular compartments most limit interpretation in adult or tumor organoid systems?